Global Sedative - Hypnotic Drugs Market, By Disease Type (Sleep Disorders, Anaesthesia, Pain, Others), Drug Class (Benzodiazepines, Barbiturates, Antihistamines, Nonbenzodiazepine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.
Sedative - Hypnotic Drugs Market Analysis and Size
Sedative-hypnotic drugs are a class of drugs that are used to maintain or induce sleep. A sedative drug moderate’s excitement calms the brain, and decreases activity, whereas hypnotic drug results in drowsiness to facilitate the onset and maintenance of a state of sleep that resembles natural sleep. Sedative hypnotics are generally available as benzodiazepines, barbiturate, sedating antihistamines, and z‐drugs. Some of the prescription hypnotic-sedative drugs are Ambien (zolpidem), Butisol (butabarbital), Estazolam, Silenor (doxepin), Edluar (zolpidem), Intermezzo (zolpidem), Flurazepam, Restoril (temazepam), and Zolpimist (zolpidem).
Data Bridge Market Research analyses that the global sedative - hypnotic drugs market which was USD 2,954.30 million in 2022, and is expected to reach USD 4,533.50 million by 2030, and is expected to undergo a CAGR of 5.50% during the forecast period 2023-2030. This indicates that the market value. “Hospitals” dominates the end user segment of the global sedative - hypnotic drugs market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Sedative - Hypnotic Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Sleep Disorders, Anaesthesia, Pain, Others), Drug Class (Benzodiazepines, Barbiturates, Antihistamines, Nonbenzodiazepine, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Eli Lilly and Company (U.S.), Cipla Inc. (U.S.), Endo International plc (Ireland), Torrent Pharmaceuticals Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), Aurobindo Pharma (India), Lupin (India), Fresenius Kabi AG (Germany), Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hypnotics and sedatives are medications that can be used to induce sleep, reduce anxiety, or relax muscles. They work by slowing down the activity of the central nervous system. Common hypnotic and sedative drugs include benzodiazepines (such as Valium), barbiturates (such as phenobarbital), non-benzodiazepine hypnotics (such as Ambien), and antihistamines (such as Benadryl).
Global Sedative - Hypnotic Drugs Market Dynamics
Drivers
- Growing Geriatric Population
Expanding geriatric population worldwide is predicted to favour global sedative-hypnotic drugs demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for global sedative-hypnotic drugs across the globe.
- Rising Prevalence of Chronic Blood Disorders
The cases of chronic blood diseases are growing exponentially and will likely drive the worldwide global sedative - hypnotic drugs market. Increase in the prevalence of chronic diseases such as cardiovascular diseases is owing to drive the market. The rising incidences of cardiovascular diseases is a major factor driving the global sedative - hypnotic drugs market growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death.
Opportunities
- Increasing in the Number of Research and Development Activities
Increased R&D investment often leads to the discovery and development of novel sedative-hypnotic drugs with improved efficacy, safety profiles, and mechanisms of action. This can result in a more diverse and competitive market. R&D efforts can explore new therapeutic indications for sedative-hypnotic drugs. For example, research may uncover potential uses beyond traditional sleep disorders, such as anxiety-related conditions, post-traumatic stress disorder (PTSD), or even neurological disorders.
- Increasing Investment for Healthcare Infrastructure
An increase in healthcare infrastructure typically means more people have access to healthcare services, including mental health and sleep disorder treatment. This could lead to higher demand for sedative-hypnotic drugs. With better healthcare infrastructure, there may be improved diagnosis and treatment of sleep disorders and anxiety-related conditions. Healthcare professionals are more likely to identify these conditions and prescribe sedative-hypnotic drugs when necessary.
Restrains/ Challenges
- Strict Regulations and Guidelines
Many sedative-hypnotic drugs are classified as controlled substances due to their potential for misuse and addiction. This classification leads to stringent regulatory controls and prescribing limitations.
- Competition from Non-Pharmacological Alternatives
Non-pharmacological alternatives, such as cognitive-behavioral therapy (CBT), relaxation techniques, and lifestyle modifications, are gaining popularity as safer and more sustainable approaches for managing sleep disorders and anxiety. These alternatives pose a challenge to the global sedative - hypnotic drugs market, as they offer non-drug solutions with potentially fewer side effects.
- Safety Concerns and Side Effects
Sedative-hypnotic drugs can have various side effects, including drowsiness, confusion, dizziness, and impaired coordination. Prolonged or excessive use of these drugs can lead to dependency, addiction, and withdrawal symptoms. Safety concerns associated with sedative-hypnotic drugs can impact their prescription rates and patient compliance.
This global sedative - hypnotic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global sedative - hypnotic market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Sedative - Hypnotic Drugs Market Scope
The global sedative - hypnotic drugs market is segmented on the basis of disease type, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Sleep Disorders
- Anesthesia
- Pain
- Others
Drug Class
- Benzodiazepines
- Barbiturates
- Antihistamines
- Nonbenzodiazepine
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Sedative - Hypnotic Drugs Market Regional Analysis/Insights
The global sedative - hypnotic drugs market is analysed and market size insights and trends are provided by country, disease type, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global sedative - hypnotic drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global sedative - hypnotic drugs market due to growing adoption of newer technologies and increasing demand for diseases-specific treatment. Additionally, the growing presence of major key players and rising healthcare expenditure will further propel the market's growth rate within region. Europe is expected to grow during the forecast period 2023-2030 due to the surging number of myocardial infraction cases and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global sedative - hypnotic drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global sedative - hypnotic drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global sedative - hypnotic drugs market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Sedative - Hypnotic Drugs Market Share Analysis
The global sedative - hypnotic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global sedative - hypnotic drugs market.
Some of the major players operating in the global sedative - hypnotic drugs market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Cipla Inc. (U.S.)
- Endo International plc (Ireland)
- Torrent Pharmaceuticals Ltd. (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Fresenius Kabi AG (Germany)
- Abbott (U.S.)
SKU-